Trace cancer biomarker quantification using polystyrene-functionalized gold nanorods - Biomark Diagnostics

Articles and Information

September 4, 2014

Trace cancer biomarker quantification using polystyrene-functionalized gold nanorods

BioMark Diagnostics Inc.

BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.

For more information, visit Optics Infobase: http://www.opticsinfobase.org/boe/abstract.cfm?uri=boe-5-12-4101

Or download the following PDF: boe-5-12-4101

Share this post:

Categories

Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.

CSE: BUX
OTC: BMKDF
FSE: 20B

More Information

Investors

Related articles ...

biomark-press-release

News

Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships

Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to

August 11, 2025

biomark-press-release

News

Press Release – BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 – 2026

BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 –

August 11, 2025

biomark-progress-report

Articles and Information

Form 7 Monthly Progress Report June 2025

Form 7 Monthly Progress Report June 2025 Name of Listed Issuer: Trading Symbol: Number of

July 8, 2025

biomark-press-release

News

Press Release – BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving

June 3, 2025

biomark-progress-report

Articles and Information

Form 7 Monthly Progress Report May 2025

Form 7 Monthly Progress Report May 2025 Name of Listed Issuer: Trading Symbol: Number of

June 3, 2025

1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2

Pages

Latest Posts

Site Policies

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.